Purple Biotech Ltd (PPBT)
Purple Biotech Ltd (PPBT) Stock Price, Analysis & Data
| Bid | 1.66 |
| Market Cap | 2.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.49M |
| Beta | -0.54 |
| EPS (ttm) | -46.74 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.47 |
| P/B (ttm) | 0.15 |
| P/S (ttm) | n/a |
| Earnings Date | Mar 8, 2022 |
| Ask | 5.21 |
| Volume | 18,804 |
| Avg. Volume (20D) | 330,300 |
| Open | 1.50 |
| Previous Close | 1.60 |
| Day's Range | 1.43 - 1.52 |
| 52-Week Range | 1.16 - 24.00 |
| Analyst | Strong Buy |
| Price Target | 17 (1040.94%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PPBT
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment o...
Financial Performance
In 2025, Purple Biotech Ltd's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -26.39M, an increase of 264.45%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for PPBT stock is "Strong Buy". The 12-month stock price forecast is 17, which is upside of 1040.94% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
